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Genetic Testing Should Not Be Advocated as a
Diagnostic Tool in Familial Forms of Dementia
To the Editor:
In their article in the January 2000 issue of the Jour-
nal, Finckh et al. advocate the use of a molecular
diagnostic program in patients with early-onset de-
mentia (EOD) and a family history of dementia
(Finckh et al. 2000). In 36 patients with EOD, Finckh
et al. screened for mutations in the presenilin
(PSEN)–1 and -2 genes (MIM 104311 and MIM
600759, respectively), the amyloid-precursor protein
(APP) gene (MIM 104760), and the prion protein
(PRNP) gene (MIM 176640); in 12 patients, they
found mutations that were considered to be disease
causing. Finckh et al. argue that, in the absence of
specific antemortem diagnostic markers for familial
Alzheimer disease (AD) or hereditary prion disease,
molecular testing is important to ensure that treatable
dementias are not missed. Although the findings by
Finckh et al. are of interest, we think that the impli-
cations of these findings for clinical practice are se-
riously limited. We offer several arguments against the
use of genetic testing as a diagnostic tool for the dif-
ferential diagnosis of dementia in general practice.
One significant limit on the usefulness of genetic
testing arises from the distribution and prevalence of
APP, PSEN, and PRNP mutations in EOD. The use-
fulness of a clinical diagnostic test is determined, in
large part, by the composition of the patient popu-
lation. Among the disease-causing mutations found by
Finckh et al., two-thirds were associated with AD, and
one-third occurred in the PRNP gene. This distribu-
tion is surprising and does not reflect the typical clin-
ical experience. The prevalence of early-onset AD is
estimated to be 18.2–41.2 persons per 100,000 at risk,
and that of autosomal-dominant early-onset AD is es-
timated to be 5.3 persons per 100,000 at risk, whereas
the familial forms of the prion diseases, which include
familial Creutzfeldt-Jakob disease, Gerstmann-Stra¨us-
sler-Scheinkers syndrome, and fatal familial insomnia,
have an estimated incidence of only 1/10 million/year
(Haywood 1997; Campion et al. 1999). Even in highly
specialized neurological or geriatric centers, a clini-
cian will not encounter a demented population in
which 33% of patients have prion disease. The rarity
of patients with prion disease underscores the very
atypical composition of the population studied by
Finckh et al. and the limited relevance that their study
has for ordinary diagnostic practice. Furthermore, we
and others have found that, in a population-based
sample, only ∼20% of patients with early-onset fa-
milial AD have a causative mutation (Cruts et al.
1998; Kamimura et al. 1998), whereas Finckh et al.
observed a mutation in 45% of such patients. We ar-
gue that, for clinical practice, the findings in a pop-
ulation-based study are more relevant than those in
a highly selected population.
Our second concern is related to the application of
molecular screening of dementia genes in clinical prac-
tice. In contrast to the mutations in the APP gene,
which are clustered around exons 16 and 17, a large
number of rare mutations in the PSEN genes are
known to be distributed throughout the gene. More
than 50% of these PSEN mutations are genetically
“private”; that is, they are found only in a particular
patient or family (Blacker and Tanzi 1998; Cruts et
al. 1998). As shown by Finckh et al., novel mutations
are still found. Also, previously unknown mutations
are detected in the PRNP gene (Laplanche et al. 1999).
The causative effects of these are difficult to interpret.
A notorious example of misjudging the pathogenicity
of a presumed missense mutation is the Glu318Gly
substitution in the PSEN-1 gene. For example, an 86-
year-old woman fulfilling the National Institute of
Neurological Disorders and Stroke and the Alzheimer
Disease and Related Disorders Association criteria for
probable AD was referred to the Memory Clinic of
Erasmus University Medical School. Her family his-
tory revealed early- and late-onset AD in several first-
degree relatives. We therefore screened for the known
AD-associated genes, and we detected an E318G mu-
tation in the PSEN-1 gene. This substitution was ear-
lier reported as a causative mutation in patients with
familial early-onset AD (Cruts and Van Broeckhoven
1998). In 1999, however, Dermaut et al. demonstrated
that an elderly group of 256 control subjects included
9 carriers of this substitution who were not demented,
results indicating that the frequency in control sub-
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jects was similar to that found in patients (Dermaut
et al. 1999). Rather than being a pathogenic mutation,
the E318G is a rare allele, that is not associated with
either AD or dementia in general and does not influ-
ence the b-amyloid formation. In the absence of any
population data, we might have incorrectly reasoned
that our patient represented a genetic case with late
onset. This example illustrates that, even in familial
cases, studies of a large series of controls should be
performed before conclusions are drawn about the
pathogenicity and penetrance of a particular muta-
tion. For any untreatable disease with a devastating
course, as is the case in AD and prion diseases, the
burden of an incorrect molecular diagnosis should be
prevented by all possible means, since genetic testing
does not have implications for the patient alone but
also discloses predictive information to family mem-
bers, which could influence such issues as life expec-
tancy, insurability, and psychosocial well-being.
We are especially concerned by the emphasis given
to the use of molecular screening of AD genes and the
PRNP gene, in light of the importance of ascertaining
the presence of treatable dementias. First, considera-
bly easier ways to diagnose treatable dementias exist.
In clinical settings it is more straightforward to test
for the presence of a treatable dementia directly (e.g.,
by measuring levels of thyroid-stimulating hormone
level to test for dementia associated with hypothy-
roidism). Second, the presence of a mutation does not
eliminate the possibility of the coexistence of a treat-
able form of dementia. Conditions such as depression,
drug intoxication, vascular dementia, and metabolic
disorders can mimic and coincide with AD, especially
in patients with a long disease course. Even when a
major mutation is present in the family, tests for treat-
able causes of dementia should not be omitted in clin-
ical practice.
Finckh et al. report interesting data on novel mu-
tations. Furthermore, they raise an intriguing question
regarding the use of genetic testing as a diagnostic
tool. However, it is of major importance to recognize
their report’s limited applicability to clinical practice.
We argue that the contribution of genetic testing to
clinical diagnosis is small and does not counterbalance
the problems associated either with interpretation of
any mutation that is found or with secondary effects
on family members. Nevertheless, for scientific rea-
sons, genetic testing is very worthwhile. Testing may
increase our knowledge about the different mutations,
which could have clinical applications in the future.
However, the limits of current knowledge are too
great to justify clinical use of genetic testing in the
diagnostic process.
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Reply to Croes et al.
To the Editor:
Croes et al. (2000 [in this issue]) make the point that
genetic testing as a diagnostic tool shows poor per-
formance in differential diagnosis in general medical
practice. We fully agree with this comment. Therefore,
one of the goals of our study (Finckh et al. 2000) was
to establish criteria that would increase the chance of
identifying a pathogenic mutation in the setting of a
specialized clinic. Indeed, among patients who had
both onset at an early age and positive family history
for early-onset dementia (EOD), diagnostic sequenc-
ing identified disease-relevant mutations in 150% of
the patients analyzed by us. Another notable result of
our study was the finding of four prion mutations
among the 36 EOD patients, which suggested that
atypical forms of prion disease may remain underdi-
agnosed. This assumption is supported by indepen-
dent observations, such as those made by two coau-
thors of the letter by Croes et al. (2000), who found
a PRNP insertion mutation in a patient with both
prion disease and ante mortem diagnosis of familial
Alzheimer disease (FAD) (Dermaut et al. 1998).
We agree with Croes et al. that assessment of the
relevance of previously unknown mutations is a dif-
ficult issue. Nonetheless, in recent screening studies
of FAD, 72%–83% of the sequence changes corre-
sponded to pathogenic mutations already reported
(Kamimura et al. 1998; Campion et al. 1999). In our
study, 58% of the mutations had been previously de-
scribed by others. Repeated identification of any given
rare mutation in a rare disorder, together with the
absence of the mutation in control probands, signif-
icantly increases the likelihood that it has causative
effects.
We were pleased to see that Croes et al. agree with
our conclusion that E318G in PS1 is a nonpathogenic
polymorphism and that they reemphasize the impor-
tance of a careful and critical analysis of the literature.
The importance of early and disease-specific diagnosis
of EOD as a way of identifying treatable forms of
dementia is an issue separate from our assertion that
diagnostic sequencing of the four known EOD genes
may provide important information for proper clinical
and genetic counseling in the early phases of the
disorder.
ULRICH FINCKH,1 TOMAS MU¨LLER-THOMSEN,2
ULRIKE MANN,2 CHRISTIAN EGGERS,3
JOSEF MARKSTEINER,5 WOLFGANG MEINS,4
GIULIANO BINETTI,6 ANTONELLA ALBERICI,6
CHRISTOPH HOCK,7,8 ROGER M. NITSCH8
AND ANDREAS GAL1
Departments of 1Human Genetics, 2Psychiatry,
and 3Neurology, University Hospital Eppendorf,
University of Hamburg, and 4Albertinen-Haus,
Geriatric Centre, Hamburg; 5Clinic of Psychiatry,
University of Innsbruck, Innsbruck; 6IRCCS Centro
S. Giovanni di Dio, Alzheimer Disease Unit,
Brescia, Italy; 7Department of Psychiatry, University
of Basel, Basel, and 8Department of Psychiatry
Research, University of Zurich, Zurich
References
Campion D, Dumanchin C, Hannequin D, Dubois B, Bel-
liard S, Puel M, Thomas-Anterion C, Michon A, Martin
C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage
V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T
(1999) Early-onset autosomal dominant Alzheimer dis-
ease: prevalence, genetic heterogeneity, and mutation
spectrum. Am J Hum Genet 65:664–670
Croes EA, Dermaut B, van der Cammen C, van Broeckhove
C, van Duijn CM (2000) Genetic testing should not be
advocated as a diagnostic tool in familial forms of de-
mentia. 67:000–000
Dermaut B, De Jonghe C, Cras P, Backhovens H, Slooter
AJC, Hofman A, Breteler MM, van Duijn CM, Hendriks
L, van Broeckhoven C, Cruts M (1998) Variable expres-
sion of the Glu318Gly mutation in presenilin-1 suggests
reduced penetrance. Paper presented at the Foundation
IPSEN conference, Epidemiolgie de la Maladie
d’Alzheimer: Du Ge`ne a` la Pre´vention. Paris, May 25
Finckh U, Mu¨ller-Thomsen T, Mann U, Eggers C, Mark-
steiner J, Meins W, Binetti G, Alberici A, Hock C, Nitsch
RM, Gal A (2000) High prevalence of pathogenic mu-
tations in patients with early-onset dementia detected by
sequence analyses of four different genes. Am J Hum Ge-
net 66:110–117
Kamimura K, Tanahashi H, Yamanaka H, Takahashi K,
Asada T, Tabira T (1998) Familial Alzheimer’s disease
genes in Japanese. J Neurol Sci 160:76–81
1036 Letters to the Editor
Address for correspondence and reprints: Dr. Ulrich Finckh, Universita¨ts-
klinikum Hamburg-Eppendorf, Institut fu¨r Humangenetik, Butenfeld 42,
22529 Hamburg, Germany. E-mail: finckh@uke.uni-hamburg.de
q 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6704-0033$02.00
Am. J. Hum. Genet. 67:1036–1039, 2000
The Efficiency of Pooling in the Detection of Rare
Mutations
To the Editor:
After citing a variety of uses of pooled testing in ge-
netic studies, Amos et al. (2000) suggested that mu-
tations in individual patients could be detected more
efficiently by being tested in pools. A typical muta-
tion-detection protocol requires that many segments
of the gene—for example, an amplicon consisting of
one or a few close exons—need to be evaluated for
detection of a mutation. Thus, even if the mutation
has a prevalence of ∼2%, as in the case of BRCA1 or
BRCA2 in Ashkenazim (Hartge et al. 1999), the prob-
ability that any segment will contain a mutation is
much smaller, perhaps on the order of .0005–.005.
The use of pools or groups of samples to identify
individuals or to estimate the prevalence of such a
rare characteristic has been extensively studied in the
statistical literature (Dorfman 1943; Sobel and Elash-
off 1972; Gastwirth and Hammick 1989; Tu et al.
1995; Brookmeyer 1999). Using the corrected formula
(see the erratum by Amos et al. [in this issue]) for the
number of runs or tests needed to identify individuals
with a mutation, one can fully appreciate the potential
of pooling methods. A variant of the grouping pro-
cedure is described that in some circumstances leads
to greater gains in efficiency when grouped testing is
utilized.
The sensitivity of an assay—that is, the probability
that a mutation will be detected, given that at least
one member of the pool has it—is a potential limiting
factor in practice. For screening of individuals to de-
termine their carrier status, the sensitivity should be
as close as possible to 100%. For detection of mu-
tations by multiplex single-nucleotide primer exten-
sion, 100% sensitivity was achieved in pools of size
10–20 but dropped to 80% in pools of 30 (Krook et
al. 1992). When denaturing high-performance liquid
chromatography was used to identify BRCA muta-
tions, 100% sensitivity was observed for several am-
plicons studied in groups of size five to nine (J. Rutter,
personal communication). Thus, for the largest pool
size for which a mutation detector is 100% sensitive,
it is helpful to know the largest mutation prevalence
for which pooling is efficient.
Suppose that the prevalence of a mutation in a sin-
gle unit (exon or amplicon) being studied is p and
that n individuals donate samples. For pools of size
r, the probability, g, that at least one member of the
pool has a mutation is . Assume that ther1 2 (1 2 p)
test is 100% accurate in classifying a pool as having
or not having a mutation. Since Y, the number of runs
or tests that need to be done without pooling is n, for
any pooling protocol in which the ratio of the ex-
pected value (y) of , the strategy saves runs.Y:n ! 1
We denote this ratio by F, for fraction of tests required
relative to individual testing; and the efficiency of a
pooling method is , the fraction of tests saved.1 2 F
When the classical single-stage pooling method (Dorf-
man 1943), which retests, one at a time, the individ-
uals in a positive pool, is used, the expected number
of runs needed to completely identify all the mutations
in the segment under study in the sample of n indi-
viduals is
n
E(Y) p 1 ng . (1)( )r
The derivation follows. The probability that a pool
contains a mutation, which implies that it will test
positive, is g. Since all r individuals in the pool will
be tested, a positive pool receives a total of tests.r 1 1
The probability that a pool is negative is ( ).1 2 g
Those pools are classified with one test, so the ex-
pected number of tests per pool is (r 1 1)g 1 (1 2
. Since there are pools, the expectedng) p 1 1 gr r
number of tests is given by equation (1). Note that
the prevalence, p, enters into equation (1) because it
determines the probability, g, that a pool is positive.
Amos et al. (2000) also considered the situation in
which there is a probability b, of a false-positive result
in a pool—that is, is the specificity of the mu-1 2 b
tation-detection process while the sensitivity remains
perfect. The same reasoning that led to equation (1)
shows that the expected number, y, of runs or tests is
given by
1 ry p n 1 [1 2 (1 2 b)(1 2 p) ] . (2){ }r
From equations (1) and (2), we can calculate the
range of values of p for which the ratio of the expected
number, y, of tests or runs (Y) to the total sample size,
n, is !1, which implies that pooling is at least as ef-
ficient as individual testing. We also present the largest
p value, p.5, for which , which indicates that
y ! .5n
pooling will result in a substantial savings in the ex-
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Table 1
Mutation Prevalence for Which Pooling Is Efficient,
as a Function of Pool Size
POOL
SIZE
LARGEST PREVALENCE FOR WHICH ISyn
!1 !.5
b p 0 b p .05 b p 0 b p .05
2 .293 .275 Not possible
3 .307 .295 .059 .043
4 .293 .284 .069 .057
5 .275 .268 .069 .059
7 .243 .237 .061 .054
10 .206 .202 .050 .045
12 .187 .184 .044 .040
15 .165 .162 .037 .034
20 .139 .137 .029 .027
25 .121 .119 .024 .022
40 .087 .085 .016 .014
50 .075 .074 .013 .012
75 .056 .055 .009 .008
100 .045 .045 .007 .006
Table 2
Optimal Pooling Size and Fraction of Tests Required,
Relative to Individual Testing, for Two Pooling Methods
p
OPTIMAL POOL SIZE (% OF TESTS REQUIRED)
b p 0 b p .05
Dorfman One Step Dorfman One Step
.2 3 (82.1) 4 (93.1) 3 (84.7) 4 (94.7)
.1 4 (59.4) 5 (60.9) 4 (62.7) 5 (62.6)
.05 5 (42.6) 8 (40.6) 5 (46.5) 7 (41.6)
.01 11 (19.6) 14 (16.0) 11 (24.0) 15 (16.9)
005 15 (13.9) 20 (11.0) 15 (18.5) 21 (11.6)
.001 32 (6.3) 45 (4.7) 33 (11.1) 47 (5.1)
.0005 45 (4.5) 63 (3.3) 46 (9.3) 66 (3.6)
.0001 100 (2.0) 142 (1.4) 103 (6.9) 149 (1.6)
pected number of tests. For the case of perfect tests,
these values of p1 and p.5 are given by
1
1r1 2 1 r r
p < 1 2 and p < 1 2 . (3)1 .5 ( )( )r 2r
When the specificity is , the equations become1 2 b
1 1
1r r.5 1 r1
p < 1 2 and p < 1 2 . (4)( )1 .5[ ]r(1 2 b) 1 2 b
In table 1, I present the values of p1 and p.5 that
are obtained from equations (3) and (4), as a function
of r, the pool size. The results for p1 indicate that
pooling in relatively small pools, up to size five or six,
can be efficient for values of . Moreover, poolsp < .25
of size <10 can save at least half of the runs, for
prevalences <.045, even with a 5% false-positive rate.
Indeed, a small lack of specificity does not have a
major impact on the range of prevalences for which
pooling is useful. For the exons and amplicons oc-
curring in DNA mutation research, in which the prev-
alence of a mutation at a specific segment being ex-
amined is likely to be near .001, pools of 40–100
individual samples would be quite efficient. Of course,
this assumes that the sensitivity of the test remains
perfect in such samples. Thus, the major limitation in
the use of pooling techniques is the maximum size of
the group for which the sensitivity of the test is es-
sentially 1.
For a specific prevalence p, the optimum pool size
is obtained by differentiating equations (1) and (2),
respectively, and by setting the derivative to 0. When
the test used has perfect sensitivity and specificity, r
satisfies
1
r ln (1 2 p) 1 ln ln p 22 ln r ;( )1 2 p
when the specificity is 12b, the optimum pool size r
satisfies
1
ln (1 2 b) 1 r ln (1 2 p) 1 ln ln p 22 ln r .( )1 2 p
The values of r that yield the optimum pool size for
a range of prevalences is given in table 2. A small
false-positive rate ( ) does not have a notice-b p .05
able impact on the optimal group size but does di-
minish the efficiency gain in the very-small-prevalence
setting when large pools are possible. The results in
table 2 indicate that pooling strategies have a greater
potential of improving the efficiency of mutation test-
ing than previous results had indicated; for example,
when , the data in table 2 indicate that, forp p .01
the Dorfman procedure, the optimal pool size is 11
and the expected number of tests is 20%–24% of the
number, n, of individuals, depending on whether
or .05.b p 0
Although a complex multistage sampling protocol
may not be appropriate when the optimal pool size
is !10 (Amos et al. 2000), a one-step procedure can
improve the efficiency of grouping. Consider a pool
size . If the pool tests negative, then all unitsr p 2m
are mutation free. When a pool tests positive, it is
divided into two pools of size m that are tested. For
rare mutations, usually only one of the two pools will
be positive, so only m further tests are needed. A sim-
ple upper bound, yu, for the expected number, y, of
tests used by this one-step method is obtained by as-
suming that, in a positive pool, if there are two or
1038 Letters to the Editor
more positive individuals, both half-groups will test
positive and all r units will need to be tested. When
the false-positive rate for testing a group of size r is
b, it is reasonable to assume that the error rate of the
test for a pool with half as many individuals ( ) isr2
. Denote the probability that a pool has exactly oneb2
positive individual by . In this case,r21h p rp(1 2 p)
the expected number of tests for a pool is
b r rb
1 1 g(2 1 r) 1 h 2 1 1 (1 2 g)b 2 1 . (5)( ) ( )2 2 2
The fraction, F, of tests needed relative to individual
testing is times equation (5). When , the upper1 b p 0r
bound for F for the one-step method becomes
n hr
y p 1 1 g(2 1 r) 2 .u ( )[ ]r 2
The optimal pool size and fraction of tests with regard
to the size, n, of the population screened, as required
by the Dorfman and one-step procedures, are given
in table 2. When the tests are perfect, the one-step
procedure does not yield a substantial increase in ef-
ficiency until fairly large pools of a very-low-preva-
lence mutation can be pooled. The one-step method
provides efficiency gains over a larger range of prev-
alence values and modest pool sizes when there are
false-positive pools. This occurs because those pools
are truly negative and because there is a very high
probability that the two half-pools will be classified
correctly by the two tests.
The results indicate that pooling should be quite
helpful when a large population is being screened for
relatively rare genetic mutations, especially when the
prevalence of a mutation in an exon or amplicon is
likely to be !.001. As improved technology enables
larger pools to be examined (Zarbl et al. 1998), the
efficiency of the one-step method should reduce the
costs substantially; for example, if the prevalence is
.005 and 20 individual samples can be pooled, the
number of tests needed is only ∼11% of the number
of individuals screened. Greater savings can be
achieved, at low prevalences, with multistage (Brook-
meyer 1999) or repooling (Munoz-Zanzi et al. 2000)
plans.
The formulas for the optimum pool size depend on
the prevalence of the mutation in the amplicon as-
sayed. Since this may not be known precisely, one can
adopt a two-stage procedure (Hughes-Oliver and
Swallow 1994) that changes the pool size on the basis
of the estimated prevalence for a partial sample. The
results in table 2 can be used to determine the group
size for the remaining analyses.
There are several other potential applications of
pooling to mutation detection. The methods discussed
both here and by Amos et al. (2000) assume perfect
sensitivity. In practice, errors occur, so it is useful to
use pooling methods to retest a sample of the screened
negatives, both to confirm that the sensitivity remains
essentially perfect and to ensure that individuals with
the mutation are not missed. Such a procedure has
been shown to be a cost-effective quality-control
method for blood screening (Gastwirth and Johnson
1994). Group testing, without identification of indi-
viduals, has also been shown to yield accurate esti-
mates of the prevalence of a rare disease or trait (Gas-
twirth and Hammick 1989), while preserving the
privacy of participants.
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